Clinical and biochemical studies with controlled-release levodopa/carbidopa

Area of Science:

• Neurology
• Pharmacology

Background:

• Parkinsonism management often involves levodopa/carbidopa therapy.
• Controlled-release formulations aim to improve therapeutic outcomes and reduce motor fluctuations.

Purpose of the Study:

• To evaluate the efficacy and pharmacokinetic profile of a novel controlled-release levodopa/carbidopa preparation (CR-3) in parkinsonism patients.
• To compare CR-3 with standard Sinemet regarding plasma levodopa levels and clinical response.

Main Methods:

• A study involving five patients with parkinsonism.
• Dosage titration of CR-3 to determine optimal levels.
• Measurement of plasma levodopa concentrations.
• Assessment of clinical response, including 'off' periods and dystonia.

Main Results:

• Optimal CR-3 dosage was three times higher than Sinemet, yielding higher plasma levodopa concentrations.
• CR-3 did not significantly reduce plasma levodopa fluctuations or clinical response variability.
• Two patients experienced benefits, with reduced 'off' times and dystonia.
• Two patients showed worsened outcomes despite higher levodopa levels.

Conclusions:

• CR-3 may benefit a subset of severely affected parkinsonism patients.
• Understanding factors influencing levodopa absorption from sustained-release forms is crucial.
• Further investigation into the consequences of prolonged elevated plasma levodopa is warranted.